Lords Mark targets April 2027 launch for AI breast cancer screening
- Final clinical trials approved for USA, Great Britain, and Europe
- Commercial launch targeted for April 2027 pending regulatory clearances
- Phase 2 trials begin January 2027 targeting 98% detection accuracy
- Global diagnostics market projected to reach $11.4 billion by 2033
*this image is generated using AI for illustrative purposes only.
Lords Mark Industries Limited advanced its AI-powered breast cancer screening technology to final clinical trials across the USA, Great Britain, and Europe. The company targets commercial placement of the radiation-free wearable device by April 2027.
The Technical Committee approved the final trial stage following the completion of clinical trials in India. These initial trials demonstrated accurate identification of cases, with data contributing to ongoing regulatory evaluation. Phase 2 trials, aiming for 98% accuracy in detecting cancer at the cell level, will commence in January 2027.
Technology and market potential
The technology utilizes high-precision thermal sensors and AI-driven temperature mapping to identify abnormalities without radiation. It is designed to be painless, portable, and battery-operated, enabling deployment in areas with limited electricity access. The global breast cancer diagnostics market was valued at $5.9 billion in 2025 and is projected to reach $11.4 billion by 2033, growing at a CAGR of 8.8%.
| Metric | Value | Context |
|---|---|---|
| Market Size (2025) | $5.9 billion | Global breast cancer diagnostics |
| Projected Size (2033) | $11.4 billion | Growth at 8.8% CAGR |
| Imaging Share | 51.6% | Current dominant segment |
| Target Accuracy | 98% | Phase 2 cell-level detection |
Regulatory and commercial roadmap
Lords Mark is progressing through regulatory evaluation in India, with CDSCO approval in process. The company is also addressing requirements for European conformity and US FDA pathways. Key regulatory milestones are targeted for completion before March 2027, subject to clinical outcomes and independent verification.
The company has made representations to authorities for inclusion in national breast cancer screening programmes and for insurance coverage consideration through the Insurance Regulatory and Development Authority of India (IRDAI). This aims to improve affordability and accessibility.
Strategic collaboration
The development is a collaboration with the Centre for Materials for Electronic Technology (C-MET), combining C-MET's R&D expertise with Lords Mark's manufacturing and distribution capabilities. The objective is to commercialise indigenous healthcare technology at scale.
Sachidanand Upadhyay, Managing Director, stated that the approval marks an important milestone in establishing a robust clinical and regulatory pathway for an accessible screening solution.
How might the FDA's specific requirements for AI-driven medical devices impact Lords Mark's timeline for US market entry compared to its European and Indian pathways?
What competitive response can be expected from established imaging giants like GE Healthcare or Siemens Healthineers as radiation-free alternatives gain clinical traction?
Will the proposed insurance coverage in India significantly accelerate adoption rates, or will reimbursement challenges persist despite regulatory approval?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
